Drug for mild AD enters next wave of study.
D000544:Alzheimer Disease / Q000188:drug therapy*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D004311:Double-Blind Method; D006801:Humans; D010919:Placebos
D061067:Antibodies, Monoclonal, Humanized; D010919:Placebos; C550616:solanezumab